drugset
drugset / Trial / NCT06426485

To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets

NCT06426485 ↗

Phase 4 Not yet recruiting 736 enrolled Luye Pharma Group Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multicenter, randomized withdrawal, double-blind, parallel, placebo-controlled design clinical trial of Toludesvenlafaxine Hydrochloride Extended-Release Tablets to evaluate the long-term efficacy and safety in the treatment of Chinese patients with depression.

Timeline

Start
2024-05-30
Primary completion
2027-02-28
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Toludesvenlafaxine Small molecule 80 mg Oral
Subject Toludesvenlafaxine Small molecule 160 mg Oral

Indications

major depressive disorder